Join
Live feed
·
PRReleasevia Quantisnow
Channel Therapeutics Corporation logo

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

ByQuantisnow·Wall Street's wire, on your screen.
CHRO· Channel Therapeutics Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CHRO (Channel Therapeutics Corporation) and more on Quantisnow.